Pre- versus post-dilution haemofiltration: a prospective randomised cross-over study
| ISRCTN | ISRCTN38768865 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN38768865 |
| Protocol serial number | N/A |
| Sponsor | Academic Medical Centre (Netherlands) |
| Funder | Internally funded (Netherlands) |
- Submission date
- 05/07/2005
- Registration date
- 06/07/2005
- Last edited
- 14/09/2009
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Urological and Genital Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Not provided at time of registration
Contact information
Mrs Anne-Cornelie de Pont
Scientific
Scientific
Academic Medical Center
Meibergdreef 9
Amsterdam
1105 AZ
Netherlands
| Phone | +31 (0)20 5669111 tracer 59229 |
|---|---|
| a.c.depont@amc.uva.nl |
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Randomised controlled trial |
| Secondary study design | Randomised controlled trial |
| Scientific title | |
| Study acronym | PREPOST |
| Study objectives | Predilution prolongs extracorporeal circuit survival time during continuous venovenous hemofiltration, due to a decrease in platelet activation and thrombin generation. |
| Ethics approval(s) | Not provided at time of registration |
| Health condition(s) or problem(s) studied | Acute renal failure |
| Intervention | Continuous venovenous haemofiltration, predilution versus postdilution |
| Intervention type | Other |
| Primary outcome measure(s) |
Extracorporeal circuit survival time |
| Key secondary outcome measure(s) |
Platelet activation, thrombin generation, urea clearance |
| Completion date | 01/01/2002 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Sex | All |
| Target sample size at registration | 7 |
| Key inclusion criteria | Eight critically ill patients with an indication for renal replacement therapy |
| Key exclusion criteria | Recent bleeding, treatment with aspirin within one week before inclusion or with therapeutic doses of unfractionated or low molecular weight heparin within 12 hours before inclusion or results of routine coagulation tests such as protrombin time (PT) and activated partial thromboplastin time (APTT) exceeding twice the upper limit of normal |
| Date of first enrolment | 01/12/2000 |
| Date of final enrolment | 01/01/2002 |
Locations
Countries of recruitment
- Netherlands
Study participating centre
Academic Medical Center
Amsterdam
1105 AZ
Netherlands
1105 AZ
Netherlands
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Not provided at time of registration |
| IPD sharing plan |
